产品名称
Anti-Sodium/Iodine Symporter Antibody, clone 2-2, clone 2-2, Chemicon®, from mouse
biological source
mouse
conjugate
unconjugated
antibody form
purified immunoglobulin
antibody product type
primary antibodies
clone
2-2, monoclonal
species reactivity
human
manufacturer/tradename
Chemicon®
technique(s)
immunohistochemistry: suitable
western blot: suitable
isotype
IgG1
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
unmodified
Quality Level
Gene Information
human ... SLC5A5(6528)
Application
Anti-Sodium/Iodine Symporter Antibody, clone 2-2 detects level of Sodium/Iodine Symporter & has been published & validated for use in IH & WB.
Immunoblotting. The antibody recognizes a major band at ~97 kDa and minor bands at 15 kDa, 30 kDa, 68 kDa and 160 kDa.
Immunohistochemistry on frozen tissues.
Optimal working dilutions must be determined by end user.
Immunohistochemistry on frozen tissues.
Optimal working dilutions must be determined by end user.
Biochem/physiol Actions
Sodium/Iodide Symporter (NIS)
Immunogen
Synthetic peptide corresponding to amino acids 37-54 of human NIS.
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Physical form
Format: Purified
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
未找到合适的产品？
试试我们的产品选型工具.
存储类别
10 - Combustible liquids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
S Micali et al.
The Journal of endocrinology, 216(2), 125-133 (2012-11-03)
Testicular cancer is the most frequent cancer in young men. The large majority of patients have a good prognosis, but in a small group of tumors, the current treatments are not effective. Radioiodine is routinely used in the treatment of
Elisa Sala et al.
Molecular cancer research : MCR, 6(5), 751-759 (2008-05-07)
BRAF-activating mutations have been reported in several types of cancer, including melanoma ( approximately 70% of cases), thyroid (30-70%), ovarian (15-30%), and colorectal cancer (5-20%). Mutant BRAF has constitutive kinase activity and causes hyperactivation of the mitogen-activated protein kinase pathway.
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持